These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15081133)

  • 1. Pharmaceutical evaluation of early development candidates "the 100 mg-approach".
    Balbach S; Korn C
    Int J Pharm; 2004 May; 275(1-2):1-12. PubMed ID: 15081133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compound selection for development - is salt formation the ultimate answer? Experiences with an extended concept of the "100mg approach".
    Korn C; Balbach S
    Eur J Pharm Sci; 2014 Jun; 57():257-63. PubMed ID: 24036162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing a molecular delivery system within a preclinical timeframe.
    Henck JO; Byrn SR
    Drug Discov Today; 2007 Mar; 12(5-6):189-99. PubMed ID: 17331883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
    Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K
    Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling.
    Maas J; Kamm W; Hauck G
    Eur J Pharm Biopharm; 2007 Apr; 66(1):1-10. PubMed ID: 17123801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of pH-dependent aqueous solubility of druglike molecules.
    Hansen NT; Kouskoumvekaki I; Jørgensen FS; Brunak S; Jónsdóttir SO
    J Chem Inf Model; 2006; 46(6):2601-9. PubMed ID: 17125200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
    Antal I
    Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New QSPR study for the prediction of aqueous solubility of drug-like compounds.
    Duchowicz PR; Talevi A; Bruno-Blanch LE; Castro EA
    Bioorg Med Chem; 2008 Sep; 16(17):7944-55. PubMed ID: 18701302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of high throughput technology for the screening of natural products.
    Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC
    Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept.
    Ku MS; Dulin W
    Pharm Dev Technol; 2012; 17(3):285-302. PubMed ID: 21121705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism in generic drug product development.
    Snider DA; Addicks W; Owens W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):391-5. PubMed ID: 14962588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
    Lennernäs H; Abrahamsson B
    J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the chemiluminescent nitrogen detector for solubility determinations to support drug discovery.
    Bhattachar SN; Wesley JA; Seadeek C
    J Pharm Biomed Anal; 2006 Apr; 41(1):152-7. PubMed ID: 16364585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure and surface properties of an investigational drug--a case study.
    Kiang YH; Shi HG; Mathre DJ; Xu W; Zhang D; Panmai S
    Int J Pharm; 2004 Aug; 280(1-2):17-26. PubMed ID: 15265543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives.
    Remko M; Swart M; Bickelhaupt FM
    Bioorg Med Chem; 2006 Mar; 14(6):1715-28. PubMed ID: 16263295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The importance of micronization in the design of dosage forms II. Pharmaceutical technological considerations].
    Antal I
    Acta Pharm Hung; 2006; 76(3):149-54. PubMed ID: 17094663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.